
    
      This study is intended to provide investigators and sponsor with the following information
      regarding the investigational new drug MT-3724 in patients with relapsed/refractory Chronic
      B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma:

      The maximum dose of a single course of MT-3724 given as intravenous (IV) infusions on Days 1,
      3, 5, 8, 10 and 12 at which there are negligible side effects and/or at which maximum serum
      levels and/or at which maximum effect on blood lymphocytes are observed. Four dose levels
      will be investigated.

      The changes in MT-3724 serum levels and blood lymphocytes over time following IV doses at
      different points in the study.

      The changes and kinds of clinical and laboratory effects and side effects that may occur over
      repeated courses of MT-3724 The changes in each subject's immune status and their CLL or SLL
      following one or more cycles of 6 infusions.
    
  